- Home
- TSSI vs MNPR Comparison
TSSI vs MNPR Comparison
Compare TSSI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSSI
- MNPR
- Stock Information
- Founded
- TSSI 2004
- MNPR 2014
- Country
- TSSI United States
- MNPR United States
- Employees
- TSSI N/A
- MNPR N/A
- Industry
- TSSI Professional Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- TSSI Consumer Discretionary
- MNPR Health Care
- Exchange
- TSSI Nasdaq
- MNPR Nasdaq
- Market Cap
- TSSI 572.8M
- MNPR 531.6M
- IPO Year
- TSSI N/A
- MNPR 2019
- Fundamental
- Price
- TSSI $8.61
- MNPR $78.00
- Analyst Decision
- TSSI
- MNPR Strong Buy
- Analyst Count
- TSSI 0
- MNPR 13
- Target Price
- TSSI N/A
- MNPR $97.83
- AVG Volume (30 Days)
- TSSI 2.1M
- MNPR 146.8K
- Earning Date
- TSSI 11-13-2025
- MNPR 11-13-2025
- Dividend Yield
- TSSI N/A
- MNPR N/A
- EPS Growth
- TSSI 7.63
- MNPR N/A
- EPS
- TSSI 0.19
- MNPR N/A
- Revenue
- TSSI $234,837,000.00
- MNPR N/A
- Revenue This Year
- TSSI N/A
- MNPR N/A
- Revenue Next Year
- TSSI N/A
- MNPR N/A
- P/E Ratio
- TSSI $45.84
- MNPR N/A
- Revenue Growth
- TSSI 91.66
- MNPR N/A
- 52 Week Low
- TSSI $5.63
- MNPR $16.26
- 52 Week High
- TSSI $31.94
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- TSSI 22.92
- MNPR 44.18
- Support Level
- TSSI $15.51
- MNPR $77.50
- Resistance Level
- TSSI $16.80
- MNPR $89.03
- Average True Range (ATR)
- TSSI 1.41
- MNPR 6.39
- MACD
- TSSI -0.74
- MNPR -0.84
- Stochastic Oscillator
- TSSI 3.24
- MNPR 15.78
About TSSI TSS Inc.
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.